Royalty Pharma Plc
Ownership
Ownership Structure
Who owns Royalty Pharma Plc (RPRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.8% of the shares are freely tradable; institutional investors hold 88.1%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 9.64 | 42,931,597 | -1.5 | 06/30/2026 |
| Capital Research & Mgmt Co - Division 3 | 7.92 | 35,273,770 | +0.8 | 06/30/2026 |
| BlackRock Inc | 6.25 | 27,832,977 | +7.4 | 06/30/2026 |
| FMR Inc | 5.51 | 24,513,814 | -2.5 | 06/30/2026 |
| State Street Corp | 2.77 | 12,338,229 | +12.3 | 06/30/2026 |
| T. Rowe Price Associates, Inc. | 2.51 | 11,193,657 | +478.7 | 06/30/2026 |
| Swedbank AB | 2.41 | 10,726,608 | -7.4 | 06/30/2026 |
| Baillie Gifford & Co Limited. | 2.25 | 10,015,578 | -38.0 | 06/30/2026 |
| Capital World Investors | 2.14 | 9,517,337 | +18.4 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| American Funds New Perspective A | 4.34 | 19,337,535 | -1.6 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Legorreta Pablo G. | CEO, Chairman of the Board | 1,307,820 | 86,839,248 $ | Aug 5, 2026 | direct |
| Hite Christopher | EVP & Chairman, Partnering | 293,601 | 19,495,106 $ | Aug 19, 2026 | both |
| Bassler Bonnie L | Director | 79,823 | 5,300,247 $ | Sep 30, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | Urist Marshall | EVP, Research & Investments | Sell | 4,126 | 57.10 | 235,595 |
| Sep 30, 2026 | Bassler Bonnie L | Director | Other | 642 | 58.41 | 37,496 |
| Sep 28, 2026 | Urist Marshall | EVP, Research & Investments | Sell | 4,126 | 57.88 | 238,813 |
| Sep 22, 2026 | Hite Christopher | EVP & Chairman, Partnering | Sell | 3,927 | 58.93 | 231,403 |
| Sep 22, 2026 | Hite Christopher | EVP & Chairman, Partnering | Sell | 96,073 | 58.51 | 5,621,692 |
| Aug 19, 2026 | Hite Christopher | EVP & Chairman, Partnering | Other | 16,800 | 0.00 | – |
| Aug 18, 2026 | Hite Christopher | EVP & Chairman, Partnering | Sell | 100,000 | 59.97 | 5,997,250 |
| Aug 13, 2026 | Coyne Terrance P. | EVP & CFO | Sell | 1,772 | 59.14 | 104,799 |
| Aug 13, 2026 | Coyne Terrance P. | EVP & CFO | Sell | 9,230 | 58.59 | 540,752 |
| Aug 5, 2026 | Urist Marshall | EVP, Research & Investments | Other | 8,252 | 0.00 | – |
| Aug 5, 2026 | Coyne Terrance P. | EVP & CFO | Other | 11,002 | 0.00 | – |
| Aug 5, 2026 | Hite Christopher | EVP & Chairman, Partnering | Other | 11,002 | 0.00 | – |
| Aug 5, 2026 | Legorreta Pablo G. | CEO, Chairman of the Board | Other | 65,216 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.